(ABH.L) Angel Biotechnology Holdings PLC Buy/Sell

RNS Number : 0688B Angel Biotechnology Holdings Plc 20 October 2009

20 October 2009

Angel Biotechnology Holdings plc (the "Company")

Exercise of warrants

The Company announces that application has been made for the admission to trading on AIM of 2,142,857 ordinary shares of 0.1p nominal value ("Ordinary Shares") with admission expected to take place on 23 October 2009.

The shares have been issued following the exercise of warrants at a price of 0.175p per share.

Following the issue of these shares, the Company will have 1,446,302,008 Ordinary Shares in issue with voting rights. The Company holds no shares in Treasury.

For further information:

Angel Biotechnology Holdings plc 07747 842446

Dr Paul Harper, Chairman

Grant Thornton Corporate Finance 020 7383 5100

Colin Aaronson

This information is provided by RNS The company news service from the London Stock Exchange

LISDGMZGRGVGLZG

RNS Number : 7193A Angel Biotechnology Holdings Plc 13 October 2009

TR-1: Notifications of Major Interests in Shares

Angel Biotechnology Holdings Plc

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

2. Reason for notification (please tick the appropriate box or boxes):
x

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify):______________
Barclays PLC

3. Full name of person(s) subject to notification obligation:
Barclays Stockbrokers Ltd

4. Full name of shareholder(s) (if different from 3):
06 October 2009

5. Date of transaction (and date on which the threshold is crossed or reached if different):
07 October 2009

6. Date on which issuer notified:
9% to 8%

7. Threshold(s) that is/are crossed or reached: 8: Notified Details A: Voting rights attached to shares

Class/type of shares Situation previous to the triggering Resulting situation after the triggering transaction
If possible use ISIN code transaction
Number of shares Number of voting Number of shares Number of voting rights Percentage of
rights voting rights
Direct Indirect Direct Indirect
GB00B0HZJ337 130,597,647 130,597,647 129,776,317 0 129,776,317 0.00 8.99

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting
period/date that may be acquired rights
(if the instrument
exercised/converted)

Total (A+B)

Number of voting rights Percentage of voting rights
129,776,317 8.99

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Barclays Stockbrokers Ltd

Proxy Voting:

10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14 Contact name: Geoff Smith
15. Contact telephone name: 020 7116 2913

This information is provided by RNS The company news service from the London Stock Exchange

HOLMJBFTMMJBBIL

RNS Number : 7178A Angel Biotechnology Holdings Plc 13 October 2009

TR-1: Notifications of Major Interests in Shares

Angel Biotechnology Holdings Plc

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

2. Reason for notification (please tick the appropriate box or boxes):
x

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify):______________
Barclays PLC

3. Full name of person(s) subject to notification obligation:
Barclays Stockbrokers Ltd

4. Full name of shareholder(s) (if different from 3):
30 September 2009

5. Date of transaction (and date on which the threshold is crossed or reached if different):
01 October 2009

6. Date on which issuer notified:
8% to 9%

7. Threshold(s) that is/are crossed or reached: 8: Notified Details A: Voting rights attached to shares

Class/type of shares Situation previous to the triggering Resulting situation after the triggering transaction
If possible use ISIN code transaction
Number of shares Number of voting Number of shares Number of voting rights Percentage of
rights voting rights
Direct Indirect Direct Indirect
GB00B0HZJ337 129,483,608 129,483,608 131,073,114 0 131,073,114 0.00 9.08

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting
period/date that may be acquired rights
(if the instrument
exercised/converted)

Total (A+B)

Number of voting rights Percentage of voting rights
131,073,114 9.08

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Barclays Stockbrokers Ltd

Proxy Voting:

10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14 Contact name: Geoff Smith
15. Contact telephone name: 020 7116 2913

This information is provided by RNS The company news service from the London Stock Exchange

HOLMJBFTMMTBBTL

RNS Number : 5828A Angel Biotechnology Holdings Plc 12 October 2009

12 October 2009

ANGEL BIOTECHNOLOGY HOLDINGS PLC

("Angel" or "the Company")

Angel and Materia Medica announce GMP Manufacturing Contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a fourth GMP Manufacturing contract with Materia Medica Holding, a leading pharmaceutical company in Russia. The contract, valued at circa £1.2 million, is for process development and GMP manufacture of specific antibodies. Over 90% of the value this contract will be invoiced over the next 18 months.

Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "Our relationship with Materia Medica continues to grow with the award of this fourth GMP manufacturing contract. We are very pleased to have been chosen and to have consolidated our position as the long-term manufacturing partner of this leading Russian pharmaceutical company. We have now been working with Materia Medica for over two years and in that time have worked closely with Materia Medica and the Medicines and Healthcare products Regulatory Agency (MHRA) to forge a clear regulatory path for it's products. Angel has to date contracted work with Materia Medica to a total value of circa £4 million. This is a clear reflection of Materia Medica's confidence in Angel's manufacturing and regulatory capabilities in the advanced biologics arena. We look forward to further contracts in the future to deliver Materia Medica's pipeline of EU licensed products.

Sergey Tarasov, of Materia Medica Holding R&D department, said: "We are delighted to award a further GMP contract to Angel. As Materia Medica's established manufacturer for our antibody based products, Angel provides a fully integrated service offering, with the necessary manufacturing and regulatory experience to allow licensing of our products in the EU. We look forward to continuing our relationship with Angel on future projects."

For further information, please call: Angel Biotechnology Holdings plc Tel: +44 (0) 131 445 6077
Gordon Sherriff - COO Tel: +44 (0) 7951 057016

Grant Thornton Corporate Finance
Philip Secrett, Colin Aaronson Tel+44 (0) 20 7383 5100

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. Angel specializes in the provision of advanced biologics including autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com.

About Materia Medica Holding

OOO "NPF "Materia Medica Holding", founded in 1992, now is one of the top manufacturers of homeopathic drugs in the Russian Federation and CIS countries.

Materia Medica Holding is the 6th largest Russian pharmaceutical company by sales with a focus on OTC drugs production. It is one of the major companies operating in this segment of the Russian market.

Recent successful development of a novel class of antibody-based therapeutics switched the strategic priorities of the company to manufacturing of oral ultra-low doses of antibodies produced by homeopathic technology. Patented technology, proven efficacy and safety, favorable benefit/risk ratio are the key distinctive features of novel drugs. Currently the company manufactures and markets the drugs for the treatment of many unmet medical needs: anxiety, alcohol addiction, erectile dysfunction, viral infections, benign prostate hyperplasia, rheumatoid arthritis/osteoarthritis, chronic heart failure, allergy etc.

Further information at www.materiamed.com

This information is provided by RNS The company news service from the London Stock Exchange

CNTUAOURKVRRAUA